Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (6230)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
Dec 24, 2023 (publication date) through Sep 28, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Clinical Oncology
ISSN
2218-4333
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Wang N, Chen FL, Pan L, Teng Y, Wei XJ, Guo HG, Jiang XM, Huang L, Liu SC, Liang ZL, Li WY. Clinical outcomes of newly diagnosed primary central nervous system lymphoma treated with zanubrutinib-based combination therapy. World J Clin Oncol 2023; 14(12): 606-619 [PMID: 38179402 DOI: 10.5306/wjco.v14.i12.606] |
|---|---|
| URL: | https://www.wjgnet.com/2218-4333/full/v14/i12/606.htm |
| Number | Citing Articles |
| 1 |
Shuai Tan, Huizhen He, Jing Ni, Yixian Guo, Huanyuan Wang, Zehao Cai, Mingyue Shang, Yaofang Cao, Yumeng Li, Yaochi Chen, Hong Zhao, Li Su, Ronghua Hu, Xiaoli Chang, Wanling Sun. Meta‐analysis evaluating the efficacy and safety of various Bruton tyrosine kinase (BTK) inhibitors for central nervous system lymphoma: Novel covalent BTK inhibitors, except for ibrutinib, also demonstrate good efficacy in the treatment of primary central nervous system lymphoma. Cancer 2025; 131(18) doi: 10.1002/cncr.70083
|
| 2 |
Leonardo S Lino-Silva, Sabrina B Martínez-Villavicencio, Luisa Fernanda Rivera-Moncada. Bruton’s tyrosine kinase inhibitors in primary central nervous system lymphoma: New hopes on the horizon. World Journal of Clinical Oncology 2024; 15(5): 587-590 doi: 10.5306/wjco.v15.i5.587
|
| 3 |
Elisa Aquilanti, Elizabeth Herrity, Lakshmi Nayak. Novel Therapies for Primary Central Nervous System Lymphomas. Current Neurology and Neuroscience Reports 2024; 24(12): 621 doi: 10.1007/s11910-024-01376-5
|
| 4 |
Wenhua Wang, Bingyi Wang, Yifei Sun, Lihua Qiu, Zhengzi Qian, Shiyong Zhou, Zheng Song, Wei Li, Xudong Zhang, Lanfang Li, Xianhuo Wang, Huilai Zhang. Clinical outcomes of newly diagnosed PCNSL treated with rituximab-methotrexate-cytarabine with or without ibrutinib: a retrospective study. Frontiers in Immunology 2025; 16 doi: 10.3389/fimmu.2025.1579483
|
| 5 |
Sakshi Khurana, Qian Nie, Kala F. Schilter, Honey V. Reddi. Demonstrating the clinical utility of genomic profiling using cerebrospinal fluid to inform management of central nervous system tumors – a meta analysis of the literature. The Journal of Liquid Biopsy 2025; 9: 100317 doi: 10.1016/j.jlb.2025.100317
|
| 6 |
Michel Wakim, Mariana Mezher, Ariel Perez-Perez, Arun Maharaj, Yazmin Odia, Manmeet Ahluwalia, Yuliya Linhares. Novel Therapies in Primary Central Nervous System Lymphoma. Clinical Pharmacology: Advances and Applications 2025; : 97 doi: 10.2147/CPAA.S501065
|
| 7 |
Adrien Gilbert, Caroline Houillier, Carole Soussain. New treatment strategies for primary central nervous system lymphoma. Current Opinion in Oncology 2025; 37(5): 414 doi: 10.1097/CCO.0000000000001165
|
| 8 |
Budhi Singh Yadav. High-dose methotrexate and zanubrutinib combination therapy for primary central nervous system lymphoma. World Journal of Clinical Oncology 2024; 15(3): 371-374 doi: 10.5306/wjco.v15.i3.371
|